预制研究 含有聚乙烯氧化物,propyl甲基纤维素和乙基纤维素的受控释放兰胺矩阵片
Andres C Arana-Linares1,2, Paola A Caicedo3, María Francisca Villegas-Torres4
1Grupo Natura, Departamento de Ciencias Farmacéuticas y Químicas, Facultad Barberi de Ingeniería, Diseño y Ciencias Aplicadas, Universidad Icesi, Calle 18 No. 122-135, Cali 760031, Colombia.
Pharmaceutics
|September 27, 2025
概括
在控制释放矩阵片中,聚合物选择至关重要. 基甲基纤维素和聚乙烯氧化物提供卓越的性能和持续的胺释放,符合监管标准.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
背景情况:
- 修改释放矩阵片的合理设计取决于了解粉末的特性和药物释放.
- 基甲基纤维素 (HPMC),聚乙烯氧化物 (PEO) 和乙基纤维素 (EC) 在加兰他胺矩阵配方中进行了评估.
研究的目的:
- 为了评估HPMC,PEO和EC在加兰他胺矩阵配方中的物理化学,颗粒度和机械性能.
- 评估聚合物选择对粉末行为和药物释放概况的影响.
主要方法:
- 使用FTIR和DSC证实了药物聚合物兼容性.
- 颗粒度分析评估了粉末的流量,凝聚力和通风.
- 压缩性模型 (Kawakita,Heckel,Leuenberger) 描述了变形机制的特征.
主要成果:
- HPMC 显示出优异的紧缩性和持续的胺释放 (85.4% 在 12h).
- PEO使逐渐侵蚀和持续的药物输送 (88.7%在12h) 成为可能.
- EC显示矩阵完整性差,导致过早释放 (1小时时76.6%);只有HPMC和PEO符合USP标准.
结论:
- 聚合物选择显著影响粉末特性和矩阵片的性能.
- 综合颗粒度和机械评估对于开发强大的可控释放系统至关重要.
相关概念视频
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
151
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
151
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
200
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
200
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
307
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
307
Factors Influencing Drug Absorption: Pharmaceutical Parameters
403
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
403


